Bosutinib
| Generic name | Bosutinib |
| Pronunciation | boe-SUE-ti-nib |
| Brand name(s), other common name(s) | BosulifTM |
| Drug type | Tyrosine kinase inhibitor (TKI) |
| How the drug is given | By mouth |
Bosutinib is FDA approved for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.
Side effects needing medical attention:
Diarrhea; nausea; vomiting; abdominal pain; low blood cell counts; rash; anemia; fever; fatigue; headache; dizziness; cough; anaphylactic shock; myelosuppression; fluid retention; liver damage; rash.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
